In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Abeona Therapeutics (ABEO), with a price target of $17. The company’s shares closed on Friday at $8.54, close to its 52-week low of $6.94.
Yang observed:
“We believe phase 1/2 data, including patient-reported outcomes, was encouraging and with a 3-month primary endpoint, we expect top-line data could be available in 1H20. We also note that the pivotal trial will include children (the phase 1/2 trial enrolled adults only).”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 16.6% and a 45.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
Currently, the analyst consensus on Abeona Therapeutics is a Strong Buy with an average price target of $27.25, implying a 219.1% upside from current levels. In a report issued on November 27, RBC Capital also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22 and a one-year low of $6.94. Currently, Abeona Therapeutics has an average volume of 659.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Dallas, TX.
